[go: up one dir, main page]

UY35600A - "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas" - Google Patents

"composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"

Info

Publication number
UY35600A
UY35600A UY0001035600A UY35600A UY35600A UY 35600 A UY35600 A UY 35600A UY 0001035600 A UY0001035600 A UY 0001035600A UY 35600 A UY35600 A UY 35600A UY 35600 A UY35600 A UY 35600A
Authority
UY
Uruguay
Prior art keywords
prepare
methods
pharmaceutical compositions
triazolopiridine
include compounds
Prior art date
Application number
UY0001035600A
Other languages
English (en)
Inventor
Dr Michael Brüning
Dr Volker Schulze
Dr Detlef Stöckigt
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35600(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY35600A publication Critical patent/UY35600A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas que comprenden compuestos del tipo de las triazolopiridinas sustituidas de la fórmula general (I), que son como se los describe y se los define en la presente. Métodos para prepararlas. Su uso en el tratamiento o la profilaxis de determinadas enfermedades.
UY0001035600A 2013-06-06 2014-06-06 "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas" UY35600A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13170754 2013-06-06

Publications (1)

Publication Number Publication Date
UY35600A true UY35600A (es) 2015-01-30

Family

ID=48569985

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035600A UY35600A (es) 2013-06-06 2014-06-06 "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"

Country Status (36)

Country Link
US (1) US20160120854A1 (es)
EP (1) EP3003381B1 (es)
JP (1) JP2016523229A (es)
KR (1) KR20160018513A (es)
CN (1) CN105263526A (es)
AP (1) AP2015008890A0 (es)
AR (1) AR096469A1 (es)
AU (1) AU2014276870A1 (es)
BR (1) BR112015030292A2 (es)
CA (1) CA2914439A1 (es)
CL (1) CL2015003535A1 (es)
CR (1) CR20150641U (es)
CU (1) CU24283B1 (es)
CY (1) CY1119666T1 (es)
DK (1) DK3003381T3 (es)
DO (1) DOP2015000295A (es)
EA (1) EA201501177A1 (es)
ES (1) ES2652149T3 (es)
HK (1) HK1219906A1 (es)
HR (1) HRP20171888T1 (es)
HU (1) HUE034883T2 (es)
LT (1) LT3003381T (es)
MA (1) MA38642A1 (es)
NI (1) NI201500172A (es)
NO (1) NO3003381T3 (es)
PE (1) PE20152028A1 (es)
PH (1) PH12015502703A1 (es)
PL (1) PL3003381T3 (es)
PT (1) PT3003381T (es)
RS (1) RS56666B1 (es)
SG (1) SG11201509114TA (es)
SI (1) SI3003381T1 (es)
SM (1) SMT201700573T1 (es)
TN (1) TN2015000524A1 (es)
UY (1) UY35600A (es)
WO (1) WO2014195408A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008898A0 (en) * 2013-06-11 2015-12-31 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
WO2006026501A1 (en) * 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions for the treatment of cancer
CN101125124B (zh) * 2006-08-16 2011-04-20 沈阳药科大学 一种亲脂性药物固体分散体的制备方法
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
CN102512358B (zh) * 2011-12-16 2013-04-10 南京农业大学 家畜用利福昔明阴道栓剂及其制备方法
CN102626384A (zh) * 2012-04-12 2012-08-08 临沂大学 一种姜黄素混悬剂及其制备方法

Also Published As

Publication number Publication date
SG11201509114TA (en) 2015-12-30
CU24283B1 (es) 2017-11-07
PE20152028A1 (es) 2016-02-07
BR112015030292A2 (pt) 2017-07-25
AP2015008890A0 (en) 2015-11-30
SI3003381T1 (en) 2018-01-31
HUE034883T2 (hu) 2018-03-28
HRP20171888T1 (hr) 2018-01-12
AR096469A1 (es) 2015-12-30
CU20150170A7 (es) 2016-03-31
CA2914439A1 (en) 2014-12-11
SMT201700573T1 (it) 2018-01-11
NI201500172A (es) 2016-01-06
LT3003381T (lt) 2017-12-27
EP3003381B1 (en) 2017-09-13
KR20160018513A (ko) 2016-02-17
PH12015502703A1 (en) 2016-03-14
DK3003381T3 (en) 2017-12-11
PL3003381T3 (pl) 2018-02-28
EP3003381A1 (en) 2016-04-13
CL2015003535A1 (es) 2016-07-08
CN105263526A (zh) 2016-01-20
US20160120854A1 (en) 2016-05-05
CR20150641U (es) 2016-01-29
AU2014276870A1 (en) 2015-11-19
NO3003381T3 (es) 2018-02-10
ES2652149T3 (es) 2018-01-31
PT3003381T (pt) 2017-12-20
DOP2015000295A (es) 2016-03-15
CY1119666T1 (el) 2018-04-04
HK1219906A1 (zh) 2017-04-21
RS56666B1 (sr) 2018-03-30
WO2014195408A1 (en) 2014-12-11
EA201501177A1 (ru) 2016-06-30
TN2015000524A1 (en) 2017-04-06
MA38642A1 (fr) 2017-10-31
JP2016523229A (ja) 2016-08-08

Similar Documents

Publication Publication Date Title
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CO2017011851A2 (es) Compuestos novedosos
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX2017001279A (es) Usos y composiciones de la flagelina.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
CL2018002368A1 (es) Formulaciones de oritavancina
UY35610A (es) Derivados de prodroga de triazolpiridinas sustituidas
CR20150641U (es) Composiciones farmacéuticas
BR112017003227A2 (pt) composto, composição farmacêutica e uso de um composto
GT201700139A (es) Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206